HES V2.0 surpasses GALAD for HCC detection: a review of multi-dimensional biomarker scores and studies.

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-04-30 DOI:10.1080/20450923.2025.2494446

Fouad Jaber, Hashem B El-Serag

{"title":"HES V2.0 surpasses GALAD for HCC detection: a review of multi-dimensional biomarker scores and studies.","authors":"Fouad Jaber, Hashem B El-Serag","doi":"10.1080/20450923.2025.2494446","DOIUrl":null,"url":null,"abstract":"<p><p>This was a narrative review of select studies published through September of 2024. We review the shift toward multi-dimensional scores such as HCC early detection screening (HES), GALAD, ASAP, and mt-HBT represents a significant advancement in biomarker research for hepatocellular carcinoma (HCC) detection. Unlike single biomarker approaches, these scores integrate various clinical and biochemical factors to enhance predictive accuracy by reflecting different complementary aspects of disease progression and HCC oncogenesis. Proper testing and validation of biomarker scores in phase 3 biomarker studies is essential before wide use can be recommended. We also review the comparative performance of biomarker scores in phase 3 studies. The new version of HES (HES V2.0) which includes AFP, AFP L3, DCP, and changes in their levels the past one year, if available, in addition to age, platelets, albumin, ALT and underlying liver disease etiology outperforms GALAD in detecting early-stage HCC with overall 6.7% higher sensitivity, and ASAP with 13.4%-18.0% higher sensitivity, both at fixed 90% specificity. HES V2.0 is a leading candidate biomarker score for prospective testing in clinical studies of early HCC detection.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"12 1","pages":"2494446"},"PeriodicalIF":1.2000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051611/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20450923.2025.2494446","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/30 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This was a narrative review of select studies published through September of 2024. We review the shift toward multi-dimensional scores such as HCC early detection screening (HES), GALAD, ASAP, and mt-HBT represents a significant advancement in biomarker research for hepatocellular carcinoma (HCC) detection. Unlike single biomarker approaches, these scores integrate various clinical and biochemical factors to enhance predictive accuracy by reflecting different complementary aspects of disease progression and HCC oncogenesis. Proper testing and validation of biomarker scores in phase 3 biomarker studies is essential before wide use can be recommended. We also review the comparative performance of biomarker scores in phase 3 studies. The new version of HES (HES V2.0) which includes AFP, AFP L3, DCP, and changes in their levels the past one year, if available, in addition to age, platelets, albumin, ALT and underlying liver disease etiology outperforms GALAD in detecting early-stage HCC with overall 6.7% higher sensitivity, and ASAP with 13.4%-18.0% higher sensitivity, both at fixed 90% specificity. HES V2.0 is a leading candidate biomarker score for prospective testing in clinical studies of early HCC detection.

查看原文本刊更多论文

HES V2.0在HCC检测方面超过GALAD：多维生物标志物评分和研究综述

这是对2024年9月之前发表的一些研究的叙述性回顾。我们回顾了向多维评分的转变，如HCC早期检测筛查（HES）、GALAD、ASAP和mt-HBT，这代表了肝细胞癌（HCC）检测生物标志物研究的重大进展。与单一生物标志物方法不同，这些评分整合了各种临床和生化因素，通过反映疾病进展和HCC癌发生的不同互补方面来提高预测准确性。在推荐广泛使用之前，在3期生物标志物研究中对生物标志物评分进行适当的测试和验证是必不可少的。我们还回顾了生物标志物评分在3期研究中的比较表现。新版HES （HES V2.0）包括AFP、AFP L3、DCP及其过去一年的水平变化（如果有的话），以及年龄、血小板、白蛋白、ALT和潜在的肝脏疾病病因，在检测早期HCC方面优于GALAD，总体敏感性提高6.7%，ASAP的敏感性提高13.4%-18.0%，两者的特异性均为90%。HES V2.0是早期HCC临床研究中前瞻性检测的主要候选生物标志物评分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.